SCHEMBL6875751

SCHEMBL6875751

COC(=O)C=Cc1cc(-c2cc3c(cc2C)C(C)(C)CCC3(C)C)ccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.51
MAPT P10636 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
TP53 P04637 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C9 P11712 1/20 0.51
HPGD P15428 1/20 0.51
ALOX15 P16050 1/20 0.51
CYP2C19 P33261 1/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B10 Q99714 1/20 0.51
RXRA P19793 7/20 0.51
RXRG P48443 2/20 0.47
RXRB P28702 1/20 0.47
RARG P13631 5/20 0.44
RARB P10826 4/20 0.44
RARA P10276 4/20 0.41
TTR P02766 1/20 0.40
APP P05067 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6876422 0.87 RXRA (0.66) RXRARXRGRXRBRARGRARB
SCHEMBL6869955 0.81 RXRA (0.52) RXRARXRGRXRBRARGRARB
SCHEMBL8189489 0.79 RARG (0.54) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL8189493 0.79 RARG (0.54) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL6874235 0.79 RXRA (0.47) CYP1A2CYP2C9CYP2C19RXRARXRG
SCHEMBL6870966 0.78 RXRA (0.54) ALDH1A1KDM4EHPGDALOX15HSD17B10
SCHEMBL6875694 0.77 ALDH1A1 (0.46) ALDH1A1MAPTKDM4EMEN1TP53
SCHEMBL6878335 0.76 RARG (0.44) RXRARXRGRXRBRARGRARB
SCHEMBL6876044 0.75 RXRA (0.45) RXRARXRGRXRBRARGRARB
SCHEMBL6875696 0.75 APP (0.48) ALDH1A1MAPTKDM4EMEN1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825360-B1 Bicyclic aromatic compounds GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-11-30 US disclosed
US-20030135053-A1 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics BERNARDON JEAN-MICHEL 2003-07-17 US disclosed
US-20030060491-A1 Bicyclic aromatic compounds BERNARDON JEAN-MICHEL (FR) 2003-03-27 US disclosed
US-6147255-A TOPICAL AND SYSTEMIC TREATMENT OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH KERATINIZATION DISORDER WHICH HAS EFFECT ON DIFFERENTIATION AND ON PROLIFERATION CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA (FR) 2000-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060491-A1 Bicyclic aromatic compounds MITF, TYR, PAH ALDH1A1 154/4885MAPT 1996/4885KDM4E 3062/4885
US-20030135053-A1 For use in human or veterinary conditions, that may be dermatological, rheumatic, respiratory, or cardiovascular and may be used in cosmetics MITF, TYR, PAH ALDH1A1 29/4885MAPT 2871/4885KDM4E 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.